Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Refractory Multiple Myeloma-Pipeline Review, H1 2015

Refractory Multiple Myeloma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Refractory Multiple Myeloma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Refractory Multiple Myeloma-Pipeline Review, H1 2015', provides an overview of the Refractory Multiple Myeloma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Refractory Multiple Myeloma Overview 10

Therapeutics Development 11

Pipeline Products for Refractory Multiple Myeloma-Overview 11

Pipeline Products for Refractory Multiple Myeloma-Comparative Analysis 12

Refractory Multiple Myeloma-Therapeutics under Development by Companies 13

Refractory Multiple Myeloma-Therapeutics under Investigation by Universities/Institutes 18

Refractory Multiple Myeloma-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Refractory Multiple Myeloma-Products under Development by Companies 22

Refractory Multiple Myeloma-Products under Investigation by Universities/Institutes 27

Refractory Multiple Myeloma-Companies Involved in Therapeutics Development 28

4SC AG 28

AbbVie Inc. 29

Acceleron Pharma, Inc. 30

Acetylon Pharmaceuticals, Inc. 31

Actinium Pharmaceuticals, Inc. 32

Altor BioScience Corporation 33

Arno Therapeutics, Inc. 34

Array BioPharma Inc. 35

Astellas Pharma Inc. 36

Astex Pharmaceuticals, Inc. 37

Biotest AG 38

Bristol-Myers Squibb Company 39

Celgene Corporation 40

Cellectar Biosciences, Inc. 41

Chroma Therapeutics Ltd. 42

CureTech Ltd. 43

Curis, Inc. 44

Dicerna Pharmaceuticals, Inc. 45

Exelixis, Inc. 46

F. Hoffmann-La Roche Ltd. 47

GlaxoSmithKline plc 48

Immunomedics, Inc. 49

Johnson & Johnson 50

Karyopharm Therapeutics, Inc. 51

MedImmune, LLC 52

Merck & Co., Inc. 53

Millennium Pharmaceuticals, Inc. 54

MorphoSys AG 55

Novartis AG 56

Oncolytics Biotech Inc. 57

Oncopeptides AB 58

Onyx Pharmaceuticals, Inc. 59

Patrys Limited 60

Pfizer Inc. 61

Pharma Mar, S.A. 62

Pharmacyclics, Inc. 63

Piramal Enterprises Limited 64

Prolexys Pharmaceuticals, Inc. 65

Sanofi 66

Sevion Therapeutics, Inc. 67

Sigma-Tau S.p.A. 68

Solasia Pharma K.K. 69

Stemline Therapeutics, Inc. 70

Sumitomo Dainippon Pharma Co., Ltd. 71

Synta Pharmaceuticals Corp. 72

Threshold Pharmaceuticals, Inc. 73

Vivolux AB 74

Refractory Multiple Myeloma-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 81

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

4SC-202-Drug Profile 89

ACP-196-Drug Profile 91

afuresertib hydrochloride-Drug Profile 93

alisertib-Drug Profile 95

alpelisib-Drug Profile 99

ALT-801-Drug Profile 101

amrubicin hydrochloride-Drug Profile 103

AR-42-Drug Profile 105

AT-7519-Drug Profile 107

AT-9283-Drug Profile 110

bendamustine hydrochloride-Drug Profile 112

cabozantinib s-malate-Drug Profile 115

CB-5083-Drug Profile 118

Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma-Drug Profile 119

CHR-3996-Drug Profile 120

CUDC-907-Drug Profile 121

dalantercept-Drug Profile 123

daratumumab-Drug Profile 125

darinaparsin-Drug Profile 128

dasatinib-Drug Profile 130

DCRM-1711-Drug Profile 133

DKN-01-Drug Profile 135

elotuzumab-Drug Profile 137

erismodegib-Drug Profile 139

evofosfamide-Drug Profile 142

filanesib-Drug Profile 149

ganetespib-Drug Profile 151

GSK-2857916-Drug Profile 156

I131-CLR1404-Drug Profile 157

ibrutinib-Drug Profile 159

indatuximab ravtansine-Drug Profile 165

ixazomib citrate-Drug Profile 167

LCL-161-Drug Profile 170

LGH-447-Drug Profile 172

linsitinib-Drug Profile 173

marizomib-Drug Profile 175

MEDI-551-Drug Profile 177

Melflufen-Drug Profile 179

milatuzumab-Drug Profile 181

MLN-0128-Drug Profile 183

Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 185

MOR-202-Drug Profile 186

MV-NIS-Drug Profile 188

oprozomib-Drug Profile 190

P-276-Drug Profile 192

palbociclib-Drug Profile 194

panobinostat-Drug Profile 198

PAT-SM6-Drug Profile 204

pelareorep-Drug Profile 206

pembrolizumab-Drug Profile 211

pidilizumab-Drug Profile 215

plerixafor-Drug Profile 217

plitidepsin-Drug Profile 219

pomalidomide-Drug Profile 221

PRLX-93936-Drug Profile 225

Recombinant Protein for Cancer-Drug Profile 227

ricolinostat-Drug Profile 229

SAR-650984-Drug Profile 231

selinexor-Drug Profile 233

SL-401-Drug Profile 237

SNS-01T-Drug Profile 239

SST-0001-Drug Profile 240

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 241

ulocuplumab-Drug Profile 243

vemurafenib-Drug Profile 245

venetoclax-Drug Profile 248

VLX-1570-Drug Profile 251

vorinostat-Drug Profile 252

Refractory Multiple Myeloma-Recent Pipeline Updates 256

Refractory Multiple Myeloma-Dormant Projects 394

Refractory Multiple Myeloma-Discontinued Products 398

Refractory Multiple Myeloma-Product Development Milestones 400

Featured News & Press Releases 400

Appendix 409

Methodology 409

Coverage 409

Secondary Research 409

Primary Research 409

Expert Panel Validation 409

Contact Us 409

Disclaimer 410

List of Tables

Number of Products under Development for Refractory Multiple Myeloma, H1 2015 16

Number of Products under Development for Refractory Multiple Myeloma-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Refractory Multiple Myeloma-Pipeline by 4SC AG, H1 2015 33

Refractory Multiple Myeloma-Pipeline by AbbVie Inc., H1 2015 34

Refractory Multiple Myeloma-Pipeline by Acceleron Pharma, Inc., H1 2015 35

Refractory Multiple Myeloma-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 36

Refractory Multiple Myeloma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 37

Refractory Multiple Myeloma-Pipeline by Altor BioScience Corporation, H1 2015 38

Refractory Multiple Myeloma-Pipeline by Arno Therapeutics, Inc., H1 2015 39

Refractory Multiple Myeloma-Pipeline by Array BioPharma Inc., H1 2015 40

Refractory Multiple Myeloma-Pipeline by Astellas Pharma Inc., H1 2015 41

Refractory Multiple Myeloma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 42

Refractory Multiple Myeloma-Pipeline by Biotest AG, H1 2015 43

Refractory Multiple Myeloma-Pipeline by Bristol-Myers Squibb Company, H1 2015 44

Refractory Multiple Myeloma-Pipeline by Celgene Corporation, H1 2015 45

Refractory Multiple Myeloma-Pipeline by Cellectar Biosciences, Inc., H1 2015 46

Refractory Multiple Myeloma-Pipeline by Chroma Therapeutics Ltd., H1 2015 47

Refractory Multiple Myeloma-Pipeline by CureTech Ltd., H1 2015 48

Refractory Multiple Myeloma-Pipeline by Curis, Inc., H1 2015 49

Refractory Multiple Myeloma-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 50

Refractory Multiple Myeloma-Pipeline by Exelixis, Inc., H1 2015 51

Refractory Multiple Myeloma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52

Refractory Multiple Myeloma-Pipeline by GlaxoSmithKline plc, H1 2015 53

Refractory Multiple Myeloma-Pipeline by Immunomedics, Inc., H1 2015 54

Refractory Multiple Myeloma-Pipeline by Johnson & Johnson, H1 2015 55

Refractory Multiple Myeloma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 56

Refractory Multiple Myeloma-Pipeline by MedImmune, LLC, H1 2015 57

Refractory Multiple Myeloma-Pipeline by Merck & Co., Inc., H1 2015 58

Refractory Multiple Myeloma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 59

Refractory Multiple Myeloma-Pipeline by MorphoSys AG, H1 2015 60

Refractory Multiple Myeloma-Pipeline by Novartis AG, H1 2015 61

Refractory Multiple Myeloma-Pipeline by Oncolytics Biotech Inc., H1 2015 62

Refractory Multiple Myeloma-Pipeline by Oncopeptides AB, H1 2015 63

Refractory Multiple Myeloma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 64

Refractory Multiple Myeloma-Pipeline by Patrys Limited, H1 2015 65

Refractory Multiple Myeloma-Pipeline by Pfizer Inc., H1 2015 66

Refractory Multiple Myeloma-Pipeline by Pharma Mar, S.A., H1 2015 67

Refractory Multiple Myeloma-Pipeline by Pharmacyclics, Inc., H1 2015 68

Refractory Multiple Myeloma-Pipeline by Piramal Enterprises Limited, H1 2015 69

Refractory Multiple Myeloma-Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 70

Refractory Multiple Myeloma-Pipeline by Sanofi, H1 2015 71

Refractory Multiple Myeloma-Pipeline by Sevion Therapeutics, Inc., H1 2015 72

Refractory Multiple Myeloma-Pipeline by Sigma-Tau S.p.A., H1 2015 73

Refractory Multiple Myeloma-Pipeline by Solasia Pharma K.K., H1 2015 74

Refractory Multiple Myeloma-Pipeline by Stemline Therapeutics, Inc., H1 2015 75

Refractory Multiple Myeloma-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 76

Refractory Multiple Myeloma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 77

Refractory Multiple Myeloma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 78

Refractory Multiple Myeloma-Pipeline by Vivolux AB, H1 2015 79

Assessment by Monotherapy Products, H1 2015 80

Assessment by Combination Products, H1 2015 81

Number of Products by Stage and Target, H1 2015 83

Number of Products by Stage and Mechanism of Action, H1 2015 87

Number of Products by Stage and Route of Administration, H1 2015 91

Number of Products by Stage and Molecule Type, H1 2015 93

Refractory Multiple Myeloma Therapeutics-Recent Pipeline Updates, H1 2015 261

Refractory Multiple Myeloma-Dormant Projects, H1 2015 399

Refractory Multiple Myeloma-Dormant Projects (Contd..1), H1 2015 400

Refractory Multiple Myeloma-Dormant Projects (Contd..2), H1 2015 401

Refractory Multiple Myeloma-Dormant Projects (Contd..3), H1 2015 402

Refractory Multiple Myeloma-Discontinued Products, H1 2015 403

Refractory Multiple Myeloma-Discontinued Products (Contd..1), H1 2015 404

List of Figures

Number of Products under Development for Refractory Multiple Myeloma, H1 2015 16

Number of Products under Development for Refractory Multiple Myeloma-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Assessment by Monotherapy Products, H1 2015 80

Number of Products by Top 10 Targets, H1 2015 82

Number of Products by Stage and Top 10 Targets, H1 2015 82

Number of Products by Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Top 10 Routes of Administration, H1 2015 90

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 90

Number of Products by Top 10 Molecule Types, H1 2015 92

Number of Products by Stage and Top 10 Molecule Types, H1 2015 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Acceleron Pharma, Inc.

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Altor BioScience Corporation

Arno Therapeutics, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Biotest AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellectar Biosciences, Inc.

Chroma Therapeutics Ltd.

CureTech Ltd.

Curis, Inc.

Dicerna Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Immunomedics, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Novartis AG

Oncolytics Biotech Inc.

Oncopeptides AB

Onyx Pharmaceuticals, Inc.

Patrys Limited

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Piramal Enterprises Limited

Prolexys Pharmaceuticals, Inc.

Sanofi

Sevion Therapeutics, Inc.

Sigma-Tau S.p.A.

Solasia Pharma K.K.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synta Pharmaceuticals Corp.

Threshold Pharmaceuticals, Inc.

Vivolux AB

Refractory Multiple Myeloma Therapeutic Products under Development, Key Players in Refractory Multiple Myeloma Therapeutics, Refractory Multiple Myeloma Pipeline Overview, Refractory Multiple Myeloma Pipeline, Refractory Multiple Myeloma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com